Outcome of childhood epistaxis with treatment of allergic rhinitis: a randomized controlled study

Eur J Pediatr. 2023 Mar;182(3):1127-1135. doi: 10.1007/s00431-022-04701-7. Epub 2023 Jan 3.

Abstract

The purpose of this study is to (1) to determine if treatment of underlying allergic rhinitis (AR) in children will affect epistaxis outcome, (2) to compare efficacy of three outpatient AR treatment regimens in epistaxis outcomes, and (3) to investigate potential factors in the pathogenesis of epistaxis with underlying AR. A single-blind randomized-controlled study was conducted in the Otolaryngology clinic in KK Women's and Children's Hospital. Sixty children aged below 18 years with underlying untreated AR, with first presentation of epistaxis, were randomized to three different AR treatments: treatment 1, antihistamine (20 patients); treatment 2, nasal steroid spray (20 patients); and treatment 3, both antihistamine and nasal steroid spray (20 patients). Epistaxis severity and frequency were assessed. Pre-treatment, 95% of patients within each of the three treatment groups described epistaxis symptoms. Post-treatment, there was improvement in epistaxis outcome (resolution of epistaxis) with 20% (4/20), 40% (8/20), and 60% (12/20) of patients in treatment groups 1 (antihistamine), 2 (nasal steroid spray), and 3 (combined therapy) respectively, who reported resolution of epistaxis. Treatment regimens containing nasal steroid spray resulted in greater improvement of epistaxis severity and frequency. Combined therapy (treatment 3) resulted in the best epistaxis outcome at 1-month follow-up. Majority (90%) reported nose-picking/rubbing behavior.

Conclusions: Intranasal corticosteroids are superior to oral antihistamines in relieving itch or rhinorrhea in AR. Intranasal corticosteroids may be important in treating epistaxis with underlying AR, because digital trauma from itch/rhinorrhea-related nose-picking/rubbing frequently leads to epistaxis. Results from this study will be important to primary and emergency physicians, community pediatricians, and pediatric allergists and otolaryngologists.

What is known: • Childhood epistaxis commonly co-exists with allergic rhinitis (AR), causing significant symptoms and distress to patients. • There are currently no studies reporti ng on epistaxis outcome aft er treatment of underlying AR.

What is new: • This is a single-blind randomized-controlled study of 60 children aged below 18 years with underlying untreated AR, with first presentation of epistaxis to a children's hospital in Singapore Patients were randomized to three different regimens to treat AR: treatment 1, antihistamine; treatment 2, nasal steroid spray; and treatment 3, both antihistamine and nasal steroid spray. • Treatment regimens containing nasal steroid spray improved epistaxis outcomes, with combined therapy of antihistamine and nasal steroid spray resulting in the best outcome for resolution of epistaxis among the three treatment regimens.

Keywords: Allergic rhinitis; Epistaxis; Randomized controlled study.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Intranasal
  • Adrenal Cortex Hormones / therapeutic use
  • Child
  • Epistaxis* / chemically induced
  • Epistaxis* / therapy
  • Female
  • Histamine Antagonists / therapeutic use
  • Histamine H1 Antagonists / adverse effects
  • Humans
  • Nasal Sprays
  • Rhinitis, Allergic* / complications
  • Rhinitis, Allergic* / therapy
  • Rhinorrhea
  • Single-Blind Method
  • Steroids / therapeutic use
  • Treatment Outcome

Substances

  • Histamine Antagonists
  • Histamine H1 Antagonists
  • Nasal Sprays
  • Adrenal Cortex Hormones
  • Steroids